AARP Eye Center
Search
Reimportation and importation of prescription drugs from licensed pharmacies and wholesalers operating in Canada should be permitted with strong safety standards.
The Federal Trade Commission should continue monitoring restraints of trade in the generic drug industry.
Efforts to expedite FDA approval processes should ensure that patient safety remains paramount.
Federal and state policymakers should ensure that practices do not unfairly exclude competition in the prescription drug market.
Congress should fund a systematic review of the safety and efficacy of the most common dietary supplements.
The FDA should require supplement manufacturers’ labels to include possible supplement interactions with commonly prescribed prescription drugs.
Federal agencies that oversee food labeling and advertising should adopt consistent standards.